Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma

BACKGROUND: New rescue regimens are needed for pediatric refractory/recurrent low-grade glioma. Nilotinib is a tyrosine kinase inhibitor that has potential synergistic effects with vinblastine on angiogenesis, tumor cell growth, and immunomodulation. METHODS: This phase I trial aimed to determine th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vairy, Stephanie, Le Teuff, Gwénaël, Bautista, Francisco, De Carli, Emilie, Bertozzi, Anne-Isabelle, Pagnier, Anne, Fouyssac, Fanny, Nysom, Karsten, Aerts, Isabelle, Leblond, Pierre, Millot, Frederic, Berger, Claire, Canale, Sandra, Paci, Angelo, Poinsignon, Vianney, Chevance, Aurelie, Ezzalfani, Monia, Vidaud, Dominique, Di Giannatale, Angela, Hladun-Alvaro, Raquel, Petit, Francois M, Vassal, Gilles, Geoerger, Birgit, Le Deley, Marie-Cécile, Grill, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344116/
https://www.ncbi.nlm.nih.gov/pubmed/32666050
http://dx.doi.org/10.1093/noajnl/vdaa075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344116/
https://www.ncbi.nlm.nih.gov/pubmed/32666050
http://dx.doi.org/10.1093/noajnl/vdaa075

Ejemplares similares